The job of a radiation therapist involves many tasks, each of which have to be done right to ensure the patient gets the greatest benefit with the least risk. Data transfer Transferring beam arrangement and [more]
Can you be sure that the person who positions you on the radiotherapy table and delivers your prescribed dose has received the necessary training and education? Europe’s radiation therapist profession are working hard to ensure [more]
Key points The presence of cachexia is being recognised to have a negative impact on surgery and immune therapy. In the absence of pharmacological therapies multimodal treatments, such as nutrition and exercise, should be used [more]
A new report underlines that vaccination, screening, treatment and public awareness, provide the cornerstone for eliminating human papillomavirus (HPV) in Europe. The report was published by The European Cancer Organisation, Brussels on 7th October.1 The [more]
‘Tackling cancer in interesting times’ was the theme of my first Editorial for Cancer World. I wrote that at the start of February this year, at a time when Europe remained largely oblivious to the [more]
As the COVID-19 pandemic shows signs of an autumn resurgence, we look at how the ‘first wave’ impacted on the delivery of cancer care, and review responses to the Cancer World survey of clinicians on [more]
Pathology-based treatment approaches are not effective in many cases of CUP due to its elusive biology. We examine the arguments for switching to a tissue-agnostic approach that targets actionable mutations in the metastases. Metastases, but [more]
The American Association for Cancer Research (AACR) annual Cancer Progress Report for 2020, published 23 September, portrays a mixed picture. On a positive note, the report features advances in cancer treatment and falls in cancer-related [more]
In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and enzalutamide, reports the latest analysis [more]
For the first time, an investigator initiated phase 1b study tested the combination of the PARP inhibitor olaparib, and the AKT inhibitor capivasertib, and showed this combination was well tolerated and achieved durable responses in [more]